A. Gabizon

Cancer Research · 2003–2013

A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Whom A. Gabizon trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Rakesh K. Jain

Who trusts A. Gabizon overall

  1. Camilla Hald Albertsen
  2. E. Merisko-Liversidge
  3. J. Kulkarni

Papers from A. Gabizon's perspective

Ordered by how strongly the researchers A. Gabizon trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. (Journal of Clinical Oncology)
  2. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile (Science Translational Medicine)
  3. Delivering nanomedicine to solid tumors (Nature Reviews Clinical Oncology)
  4. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors (Proceedings of the National Academy of Sciences of the United States of America)
  5. Transport of molecules across tumor vasculature (Cancer Metastasis Review)
  6. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy (Nature Medicine)
  7. Openings between defective endothelial cells explain tumor vessel leakiness. (American Journal of Pathology)
  8. Pathology: Cancer cells compress intratumour vessels (Nature)
  9. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis (Nature Cell Biology)
  10. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. (American Journal of Pathology)

Their papers